奥替普拉改善急性痛风性关节炎小鼠模型疼痛和炎症的效应及机制研究

被引:9
作者
曾丹怡 [1 ,2 ]
尹诚语 [1 ]
刘伯宇 [1 ]
聂慧敏 [1 ]
李晓洁 [1 ]
陈瑞香 [1 ]
王洁 [1 ]
李园园 [1 ]
徐若瑶 [1 ]
位会娜 [1 ]
台燕 [3 ]
邵晓梅 [1 ]
王萍 [2 ]
刘伯一 [1 ]
机构
[1] 浙江中医药大学第三临床医学院浙江省针灸神经病学研究重点实验室
[2] 浙江中医药大学基础医学院
[3] 浙江中医药大学中医药科学研究院
基金
浙江省自然科学基金;
关键词
急性痛风性关节炎; 氧化应激; 疼痛; 奥替普拉; 步态;
D O I
暂无
中图分类号
R593.22 [类风湿性关节炎]; R-332 [医用实验动物学];
学科分类号
100201 [内科学]; 100402 [劳动卫生与环境卫生学];
摘要
目的建立急性痛风性关节炎(AGA)小鼠模型,观察并研究奥替普拉(Oltipraz)能否改善模型小鼠出现的关节炎症和疼痛。方法把健康C57/BL6雄性小鼠随机分为对照组(Control)、模型+溶剂组(MSU+Veh)、模型+奥替普拉高剂量组(MSU+100 mg/kg Oltipraz)、模型+奥替普拉低剂量组(MSU+30 mg/kg Oltipraz)以及模型+吲哚美辛组(MSU+10 mg/kg Indo)。除对照组注射磷酸盐缓冲液以外,其余各组小鼠右踝关节注射尿酸钠(MSU),制备AGA小鼠模型。模型制备成功前后,模型+奥替普拉组小鼠腹腔注射奥替普拉,模型+吲哚美辛组同一时间点腹腔注射吲哚美辛,其余组腹腔注射等量溶剂。采用游标卡尺对五组小鼠造模前后踝关节肿胀程度进行测量;用von Frey丝检测小鼠50%机械缩足反应阈值(50%PWT);病理学分析踝关节滑膜组织切片; Digi Gait成像系统检测小鼠步态,并分析造模前后步态行为学变化;氧化分子检测试剂盒检测小鼠踝关节氧化应激反应; q PCR技术检测踝关节组织炎症因子表达。结果与对照组相比,模型组小鼠踝关节明显肿胀,50%PWT显著降低(P <0.01)。病理学显示模型组小鼠踝关节滑膜组织相较于对照组出现明显炎性细胞浸润(P <0.05)。步态分析显示模型组小鼠相较对照组小鼠步幅长度显著缩短,脚爪触地面积显著减小(P <0.01)。与模型+溶剂组相比,模型+100 mg/kg奥替普拉组小鼠患侧50%PWT显著上升(P <0.01);踝关节肿胀程度显著减轻;步态相关参数出现显著改善(P <0.05);踝关节组织中氧化应激水平出现显著下降(P <0.05);炎性因子IL-1β、TNF-α表达水平也显著下降(P <0.01),其效果和吲哚美辛类似,而30 mg/kg无明显效果。结论奥替普拉可缓解AGA模型小鼠踝关节肿胀和关节疼痛,这一治疗作用很可能与其降低AGA小鼠踝关节组织中氧化应激水平,增加抗氧化物质表达并减少炎症因子表达有关。
引用
收藏
页码:585 / 592
页数:8
相关论文
共 17 条
[1]
IL-33/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain [J].
Yin, Chengyu ;
Liu, Boyu ;
Li, Yuanyuan ;
Wang, Jie ;
Li, Xiaojie ;
Chen, Ruixiang ;
Tai, Yan ;
Shou, Qiyang ;
Wang, Ping ;
Shao, Xiaomei ;
Liang, Yi ;
Zhou, Hong ;
Mi, Wenli ;
Fang, Jianqiao ;
Liu, Boyi .
THERANOSTICS, 2020, 10 (26) :12189-12203
[2]
Differences in Achilles tendon stiffness in people with gout: a pilot study [J].
Otter, Simon ;
Payne, Catherine ;
Jones, Anna-Marie ;
Webborn, Nick ;
Watt, Peter .
BMC MUSCULOSKELETAL DISORDERS, 2020, 21 (01)
[3]
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors [J].
Dehlin, Mats ;
Jacobsson, Lennart ;
Roddy, Edward .
NATURE REVIEWS RHEUMATOLOGY, 2020, 16 (07) :380-390
[4]
Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis [J].
Yin, Chengyu ;
Liu, Boyu ;
Wang, Ping ;
Li, Xiaojie ;
Li, Yuanyuan ;
Zheng, Xiaoli ;
Tai, Yan ;
Wang, Chuan ;
Liu, Boyi .
BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (09) :2042-2057
[5]
2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout [J].
Richette, Pascal ;
Doherty, Michael ;
Pascual, Eliseo ;
Barskova, Victoria ;
Becce, Fabio ;
Castaneda, Johann ;
Coyfish, Malcolm ;
Guillo, Sylvie ;
Jansen, Tim ;
Janssens, Hein ;
Liote, Frederic ;
Mallen, Christian D. ;
Nuki, George ;
Perez-Ruiz, Fernando ;
Pimentao, Jose ;
Punzi, Leonardo ;
Pywell, Anthony ;
So, Alexander K. ;
Tausche, Anne-Kathrin ;
Uhlig, Till ;
Zavada, Jakub ;
Zhang, Weiya ;
Tubach, Florence ;
Bardin, Thomas .
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (01) :31-38
[6]
Gout epidemiology and comorbidities.[J].Jasvinder A. Singh;Angelo Gaffo.Seminars in Arthritis and Rheumatism.2020, 3
[7]
PPARγ activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway.[J].Ya-Qun Zhou;Dai-Qiang Liu;Shu-Ping Chen;Nan Chen;Jia Sun;Xiao-Mei Wang;Dan-Yang Li;Yu-Ke Tian;Da-Wei Ye.Biomedicine & Pharmacotherapy.2020,
[8]
Prevention and treatment of gout [J].
Stamp, Lisa K. ;
Dalbeth, Nicola .
NATURE REVIEWS RHEUMATOLOGY, 2019, 15 (02) :68-70
[9]
Gouty Arthritis: A Review of Acute Management and Prevention [J].
Wilson, Liza ;
Saseen, Joseph J. .
PHARMACOTHERAPY, 2016, 36 (08) :906-922
[10]
Nrf2 activators as potential modulators of injury in human kidney cells.[J].Amandla Atilano-Roque;Xia Wen;Lauren M. Aleksunes;Melanie S. Joy.Toxicology Reports.2016,